To include your compound in the COVID-19 Resource Center, submit it here.

Building a liver powerhouse

Orphan play Lumena gets runway in NASH, other liver disorders

Building a liver powerhouse

Lumena Pharmaceuticals Inc. will use last week's $45 million series B round to support expanded Phase II testing of LUM001 in cholestatic liver disease and a planned Phase II trial for LUM002 in nonalcoholic

Read the full 377 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers